Protocol Ledger

NCT04408118 · Phase II · COMPLETED

First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC

Interventional Phase II clinical trial protocol NCT04408118 sponsored by MedSIR in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-10-05 Enrollment: 100 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04408118
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04408118
Protocol FieldVerified Registry Value
NCT IdentifierNCT04408118
Consolidated Lead SponsorMedSIR
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment100 participants (ACTUAL)
Registered Start Date2020-10-05
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI